Code
MOG-RAFX-03BZ
Panel
Active-Compendium
Molecular: Client-bill only, if ordered concurrently with Neo Comprehensive™ – Myeloid Disorders, or one of the NeoTYPE® Heme Profiles, such as Myeloid Disorders Profile, AML Prognostic Profile, or MDS/CMML Profile. See Notes if ordered alone.
Clinical
Oncology,Pathology
Flag Active
True
Orderable Test Description
The Rapid AML Therapeutic Panel analyzes 13 biomarkers through a combination of bi-directional Sanger sequencing, PCR, and FISH as listed below.
Sanger sequencing (1 gene): TP53
PCR/Fragment Analysis (5 genes): FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA
FISH probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | MLL (11q23) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) | 17p- (TP53 17p13.1, NF1 17q11.2)
Test reports include a summary of all results together.
Sanger sequencing (1 gene): TP53
PCR/Fragment Analysis (5 genes): FLT3 (ITD and TKD), IDH1/IDH2, NPM1, and CEBPA
FISH probes: 5q-, -5 (5p15, 5q31, 5q33) | 7q-, -7 (Cen 7, 7q22, 7q31) | RUNX1/RUNX1T1 (ETO/AML1) t(8;21) | MLL (11q23) | PML/RARA t(15;17) | CBFB inv(16), t(16;16) | 17p- (TP53 17p13.1, NF1 17q11.2)
Test reports include a summary of all results together.
Orderable Turn Around Time
4-5 Days for FLT3, IDH1/IDH2, and FISH. 7-10 Days for NPM1, CEBPA, and TP53.
Medical Necessity Resources
Extra Note
Please select extract & hold - DNA if specimen hold service is desired. Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
Orderable Biomarkers
NY Approved
False
Orderable Biomarkers JSON
{"Fluorescence In Situ Hybridization (FISH)": {"Translocation(s)": ["RUNX1T1/RUNX1 (ETO/AML1) t(8;21)", "RARA"], "Deletion(s)": ["5q-", "7q-"], "CNVs": ["CBFB"]}, "DNA Sequencing": {"SNVs + Indels": ["TP53", "IDH2", "IDH1", "FLT3", "CEBPA"], "CNVs": ["TP53"]}}
Keywords string
AML, acute myeloid leukemia, risk stratification, client-bill Rapid AML Therapeutic Panel
Title URL
rapid-aml-therapeutic-panel